(UroToday.com) Following presentations by Dr. Ghadjar assessing dose-intensification among patients receiving salvage radiotherapy following radical prostatectomy and by Dr. Tward looking at the clinical cell-cycle risk score to identify men who can forgo androgen deprivation therapy at the time of dose-escalated radiotherapy for prostate cancer, Dr. Valicenti provided a discussion of these data in the Oral Abstract Session: Prostate Cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).